


Provista Life Sciences

Press Kit



Contents Include:

Company Overview

Company Fact Sheet

BT Test Fact Sheet

BT Test FAQ

Media Contact:

Carol Klimas
(480) 505-4527
carolk@offmadisonave.com



PROVISTA LIFE SCIENCES COMPANY OVERVIEW

History of Provista Life Sciences

Established in 2006, Phoenix-based Provista Life Sciences is a healthcare and biotechnology development organization dedicated to bringing innovative tests for early disease detection to medical professionals and patients nationwide. The organization offers testing services in two areas: oncology and central nervous system diseases.

Provista Life Sciences CEO William Gartner founded the organization to help save and improve lives through the early detection of critical diseases facing today's population. Gartner set out to utilize his more than 35 years' experience in the environmental and medical fields, with an extensive history of product development, operational oversight and technology transfer, to develop an organization that delivers diagnostic tests never before seen on the market.

To build the organization, Gartner partnered with chief medical players, including Robert Woods, president, Provista Diagnostics, Provista Life Science's laboratory arm, who has more than 27 years of hands-on operational and management experience, and Dr. Louis Kirby, chief medical officer, with more than 18 years of drug development and clinical research experience. Gartner also tapped Randy Grimes to spearhead grant development through the National Institutes of Health and Don Webber to foster strategic alliances and partnerships. With their integral specialties, Gartner and his team began developing the breakthrough testing technologies that are changing the face of the healthcare diagnostics market.

Innovative Technologies

Gartner and his team have been actively working to bring the company's innovative tests to the public to help people live longer, healthier lives. Specifically, the organization offers two distinctive oncological tests for women, a test to aid in the early detection of Alzheimer's disease, as well as two memory tests.

Breast Cancer Detection

The Biomarker Translation Test, or, the BT Test™, is a simple blood test that aids in the early detection of breast cancer. When detected and treated in its early stages, breast cancer has a 96 percent survival rate – yet the disease kills more women than any other form of cancer. Provista Life Sciences seeks to encourage the nearly 35 million women per year who do not get screened for breast cancer to do so, as early detection provides the best chance for a cure.

The BT Test is designed to complement other testing methods to aid doctors in more accurately diagnosing breast cancer in its early stages, when life-saving treatment is most effective. Designed to be prescribed in conjunction with annual mammograms, the BT Test helps ensure that patients receive the most thorough diagnosis possible. The test is now available nationwide.

Women's Cancer Detection

Frequently undiagnosed, women's reproductive cancers – including ovarian, uterine and cervical cancer – often go undetected in their early stages, allowing the cancer to spread. To fight these deadly diseases, Provista Life Sciences created the RCP Test™. With the goal of narrowing the timeframe between cancer incidence and cancer detection, the test offers an opportunity for physicians to drastically improve their patients' treatment outcomes.

When used in conjunction with other early detection methods, such as mammograms and Pap smears, the test can help doctors accurately diagnose cancer sooner. The RCP Test measures molecular markers for the presence of a tumor in a noninvasive, effective way, offering fewer false negatives, fewer false positives and consistent results. Provista Life Sciences is in the final stages of clinical studies and hopes to bring the test to market in late 2008.

Alzheimer's Disease and Memory Loss Detection

More than 600,000 Americans are diagnosed each year with chronic, progressive dementia. Of those, 400,000 are diagnosed with Alzheimer's disease. Provista Life Sciences is meeting the need for a simple, accurate Alzheimer's test with the LymPro Test®, a blood test that is designed to work in conjunction with traditional diagnostic methods to help physicians develop a more timely and accurate diagnosis of Alzheimer's disease.

By assisting in the early detection of the disease, the LymPro Test has the potential to help doctors diagnose Alzheimer's more efficiently, allowing patients to begin treatment early, when currently approved drugs are most effective at slowing the disease's progression. Under development by Provista Diagnostics, the LymPro Test currently is involved in a National Institutes of Health Phase II Study that will be completed in the spring of 2008.

Additionally, Provista Life Sciences offers an over-the-counter self-administered test for cognitive and memory impairment: The Provista Memory Test™. The Provista Memory Test for cognition is a take-at-home test that is scored with a simple phone call to a Provista Life Sciences expert. While the Memory Test cannot diagnose a disease, it is a powerful tool to help understand if an individual has any loss of mental ability and help determine whether further action should be taken.

The Memory Test Plus is the only FDA cleared "smell test" available, as the loss of the sense of smell may indicate a medical problem that requires follow-up by a physician. Early detection of developing medical conditions can lead to early treatment and improved quality of life.

Provista Life Sciences brought both of these tests to market in early 2008, and they currently are available at Provista Life Sciences' Web site, www.ProvistaLS.com.

Setting New Standards

The organization's first line of responsibility is, and always has been, to the people who take Provista Life Sciences tests, to give them the best chance at defeating deadly diseases. Through each of its unique tests, Provista Life Sciences is at the forefront of diagnostic technologies and is setting new standards in early diagnosis testing methods.

To support the ongoing goal of continued scientific and medical research, Provista Life Sciences has assembled a Medical Advisory Group to provide input on the overall medical and study planning. The Medical Advisory Group also functions as a referral source for subjects to participate in the various studies the organization offers, allowing Provista Life Sciences to further its clinical trials and research.

The group is comprised of highly renowned experts in key medical areas including oncology, radiology, neurology and surgery, as well as a Clinical Laboratory Improvement Amendments laboratory operations specialist and a regulatory/FDA consultant.

Provista Life Sciences is dedicated to continuing to bring revolutionary technologies to the market to help save or improve the lives of people facing some of the most prevalent and serious diseases. The company is proud to have made the BT Test and the Provista Memory Test and Memory Test Plus available to the public, and looks forward to completing clinical trials for each of its additional diagnostic technologies to bring them to market in the near future.

###



PROVISTA LIFE SCIENCES COMPANY FACT SHEET

Name: Provista Life Sciences

Established: 2006

Corporate Office: 6225 N. 24th St., Suite 150
Phoenix, AZ 85016

Phone: 602-244-5500

Web site: www.ProvistaLS.com

Executive Team: William Gartner, President & CEO
Dr. Louis Kirby, Chief Medical Officer
Jim Zicarelli, Chief Finance Officer
Donald F. Weber, VP, Strategic Alliance
F. Randall Grimes, VP, Operations
Caroline Hardy, Director of Marketing
Robert V. Woods, President, Provista Diagnostics
Joel Bird, VP, Reimbursement Strategies

Overview: Provista Life Sciences is a biotechnology diagnostics development and commercialization organization focused on providing the scientific and operating management resources to advance rapidly the development and introduction of cutting-edge diagnostic technologies.

Specifically, the organization offers healthcare professionals and patients innovative tests to aid in the early detection of cancers and Alzheimer's diseases. Provista Life Sciences' breakthrough testing technologies are changing the healthcare diagnostics market by helping people live longer, healthier lives.

Cancer Tests for Women:

Provista Life Sciences offers two unique oncological tests for the early detection of cancer: the BT Test™ and the RCP Test™. The BT Test, which stands for Biomarker Translation Test, is designed to aid in the detection of breast cancer, the deadliest cancer amongst women. The test assists physicians in making an earlier and more accurate diagnosis of breast cancer when used adjunctively with a mammogram. The RCP Test, which stands for Riboflavin Carrier Protein, is a blood test that aids in the detection of several reproductive cancers including ovarian, uterine and cervical cancer.

Alzheimer's & Memory Tests:

Provista Life Sciences is on the forefront of Alzheimer's disease detection with innovative, affordable tests to aid doctors and patients in recognizing the disease in its earliest stages.

The **LymPro Test®** is a pioneering blood test designed to work in conjunction with traditional diagnostic methods to help physicians develop a timelier, conclusive diagnosis of Alzheimer's disease.

In addition to this test, the company offers two self-administered tests; the Provista Memory Test™ for cognitive and memory impairment, and The Provista Memory Test Plus™ -- the only FDA-cleared over-the-counter smell test on the market today.

Laboratory Arm:

The groundbreaking tests offered by Provista Life Sciences are conducted through its Provista Diagnostics laboratory. Provista Diagnostics is a wholly owned subsidiary of Provista Life Sciences and offers services to doctors' offices, clinics and hospitals throughout the United States.


Provista Diagnostics is a Clinical Laboratory Improvement Amendments (CLIA) registered Reference Laboratory, ensuring it follows all industry best practices and regulations. In addition to conducting the tests, Provista Diagnostics conducts extensive clinical studies to ensure the accuracy of each of its tests and technologies.

Leading Early Prevention:

Provista Life Sciences is making significant strides in the early detection of critical diseases facing today's population and is setting new standards in the diagnostic technologies industry. The company has completed clinical studies and made the BT Test available to women and physicians, and is in the clinical trials for its women's cancer technologies.

Additionally, Provista Life Sciences is dedicated to further research into central nervous system diseases, with a goal of improving the care and quality of life for people suffering from memory loss and cognitive impairment. The Provista Memory Test and Memory Test Plus currently are available at Provista Life Sciences' Web site, www.ProvistaLS.com, and the LymPro Test will be introduced to the market in summer 2008.


###



BT TEST FACT SHEET

- Name:** Biomarker Translation Test (BT Test)
- Company:** Provista Life Sciences
- About the Test:** The BT Test is a blood test used in the early detection of breast cancer. Breast cancer has a 96-percent survival rate when detected and treated early, yet there is a growing demand from women to create alternative diagnostic screening tools. The BT Test assists physicians in making an earlier and more accurate diagnosis of breast cancer when used adjunctively with a mammogram.
- Women ages 35-75 should take the BT Test in conjunction with their annual mammogram. Provista Life Sciences will file private insurance claims on behalf of women who take the BT Test and cover 100 percent of the test's cost not covered by insurance. For women who do not wish to submit an insurance claim, the BT Test is available at a cost of \$295.
- Functionality:** The BT Test uses a proprietary algorithm to evaluate the levels and relationship of multiple, cancer-associated protein biomarkers in the blood serum. This data is coupled with a patient's personal medical profile to generate a report.
- Clinical Trials:** Extensive clinical trials have been conducted on the BT Test to ensure its efficacy. The studies involved nine clinical sites and a total of approximately 400 women.
- Testing Process:** Physicians are encouraged to discuss the BT Test with their patients during their yearly exam. Once the physician prescribes the test, the woman will fill out a medical history profile. The woman then goes to a Sonora Quest Laboratory for the blood draw. The sample is sent to the laboratory arm of Provista Life Sciences, Provista Diagnostics, to be analyzed. Results are then provided to the doctor for review with the patient.
- Results:** Results are sent in the form of a report, which notes the probability that breast cancer exists in a patient's system. It is recommended that a physician review the report with their patient in order to determine the best course of action based on the test results.
- Contact:** Women and physicians looking to learn more about the BT Test should contact Provista Life Sciences at 602-224-5500 or log on to www.ProvistaLS.com.

###



BT TEST FREQUENTLY ASKED QUESTIONS

Q: What is the BT Test?

A: The BT Test, which stands for Biomarker Translation Test, is a blood test for the early detection of breast cancer, and is used in conjunction with a mammogram to help a health care provider make a more accurate and timely detection of breast cancer.

Q: How does the BT Test work?

A: The BT Test measures a select grouping of well known cancer related proteins in a blood serum sample, and by using a proprietary algorithm to combine that data with a patient's personal medical profile, a BT Score is generated that reflects the level of probability that breast cancer is present.

Q: Who should get the BT Test?

A: Provista Life Sciences recommends all women over the age of 35 get the BT Test every year along with their annual screening mammogram.

Q: Does the test tell women whether or not they have breast cancer?

A: An abnormal score on the BT Test is an indicator of an increased likelihood of having breast cancer. The actual diagnosis of cancer can only be confirmed by a tissue biopsy with the specimen examined under a microscope for tumor cells.

Q: What is the process for taking the BT Test and receiving the results?

A: A patient receives a prescription/draw authorization for the BT Test from the health care provider. The patient then takes the prescription/draw authorization to a blood draw facility such as Sonora Quest Laboratories. The patient's sample is sent to Provista Diagnostics to perform the BT Test and the results are reported directly to the prescribing physician to review with the patient.

Q: How does this test differ from genetic testing or other biomarker testing?

A: Genetic tests establish a risk estimate as to the possibility that the patient may or may not get breast cancer in the future. The BT Test looks at the existing levels of certain cancer associated proteins in the patient's blood sample and evaluates whether or not the disease is currently present based on extensive clinical trial study results.

Q: Is the BT Test covered by insurance?

A: Provista Life Sciences will file private insurance claims on behalf of women who take the BT Test and cover 100 percent of the test's cost not covered by insurance. For women who do not wish to submit an insurance claim, the BT Test is available at a cost of \$295.

Q: Is the BT Test FDA-approved?

A: The test is regulated under the FDA's Clinical Laboratory Improvements Amendment (CLIA). Provista Diagnostics, a wholly owned subsidiary of Provista Life Sciences, provides the laboratory services for the tests and is a CLIA registered reference laboratory.

Q: Where can someone go to find more information about the BT Test?

A: Patients and physicians seeking additional information on the BT Test can go to ProvistaLS.com and click on the Breast Cancer Test link at the top of the page. Here they will find information about breast cancer, about the BT Test, research conducted on the BT Test and a list of physicians who currently prescribe the test.

###